2008 is a Decisive Year for the Validation of the Asthma Target Interleukin-13
Results of two major phase II studies in asthma expected during 2008 will be a GO/NO GO milestone for the field of interleukin-13 (IL-13) antagonists.
BARCELONA, Spain | Feb 11, 2008 | The Business Intelligence firm La Merie S.L. reported today that during the year 2008 results of major phase II studies in asthma with two different interleukin-13 antagonistic antibodies are expected which will be decisive for the validation of a hot target. Interleukin-13 is regarded to have a central in the development of allergic asthma, mediating airway inflammation, obstruction and hyper-reactivity. Asthma affects at least 5 % of the population and 5 to 10 % of them suffer from severe asthma. Asthma is treated with steroids and bronchodilators, but urgently needs novel therapies. IL-13 has attracted great interest as a target for injected or inhaled biologics, including antibodies, proteins, peptides, antisense and small interfering RNA (siRNA). There are at least 6 clinical stage direct or indirect IL-13 antagonists in active development. All of them are pursuing asthma as the clinical lead indication. Further two companies are close to phase I. These results and more were found in a search and analysis conducted by La Merie Business Intelligence and published on February 11, 2008. The Brief Report can be acquired at La Merie’s News Center and Online Store PipelineReview.com (www.pipelinereview.com ).
Clinical information obtained so far from the various IL-13 antagonists indicates that neutralization of the effects of IL-13 appears to be safe and well tolerated and shows signs of clinical activity in asthma. There are various approaches to neutralize the effects of IL-13: by directly binding to IL-13 and, thus preventing the cytokine to bind to its receptor and induce signalling; by blocking one of the two receptor subunits to which IL-13 binds (the IL-13 receptor alpha and the IL-4 receptor alpha which share a common subunit for binding of IL-13). The Brief Report “Interleukin-13 (IL-13) Antibodies” compiles the individual profiles of 13 different molecules in development as direct or indirect antagonists of IL-13 in various clinical indications and provides a competitor analysis in the field. The current stage of R&D is assessed and background information on the target, the scientific rational, drug discovery approaches and clinical indications is given.
About La Merie
La Merie S.L. is a Business Intelligence enterprise fully dedicated to provide high quality R&D information to the biopharmaceutical industry. La Merie offers individual consultancy services and publishes reports and periodicals. For more information visit www.lamerie.com.
PipelineReview.com is the News Center and Online Store of La Merie Business Intelligence focused on Research and Development in the Biopharmaceutical Industry. Visitors of PipelineReview.com will find R&D relevant press releases and can receive selected R&D news from one or more of the site’s News Channels. La Merie publishes two FREE newsletters: La Merie Daily provides an overview on therapeutic areas and La Merie Biologics is the weekly bulletin for news about biologics. For free subscription and more information visit www.pipelinereview.com.
SOURCE: La Merie Business Intelligence
Also you can read this PR online at Pipelinereview.com's Press Room or at La Merie's Business Intelligence Press Room Best Regards, Pau Cuevas C/Casp 33 B 4º 2ª. 08010 Barcelona Tel + 34 93 342 91 97 Fax + 93 342 91 98 eMail: Pau.email@example.com Biotech News Center & Online Store: www.pipelinereview.com. http://www.lamerie.com
Posted: February 2008